Evidence map›Paper›PMID 36316043›Full record

ArticleCancer genomics & proteomics

Derivative Chromosome 3 Loss from t(3;6)(q12;q14) Followed by Differential

Kosuke Mizutani, Shigeaki Yokoi, Seiya Sawada, Ippei Sakamoto, Koji Kameyama, Shingo Kamei, Kouseki Hirade, Seiji Sugiyama, Kengo Matsunaga, Tetsuya Yamada and 4 more

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Kosuke MizutaniCancer Genomic Testing and Treatment Center, Central Japan International Medical Center, Minokamo, Japan; k-mizutani@cjimc-hp.jp.
Shigeaki YokoiDepartment of Urology, Central Japan International Medical Center, Minokamo, Japan.
Seiya SawadaCancer Genomic Testing and Treatment Center, Central Japan International Medical Center, Minokamo, Japan.
Ippei SakamotoBioinformatics Department, Communication Engineering Center, Electronic Systems Business Group, Mitsubishi Electric Software Corporation, Tokyo, Japan.
Koji KameyamaDepartment of Urology, Central Japan International Medical Center, Minokamo, Japan.
Shingo KameiDepartment of Urology, Central Japan International Medical Center, Minokamo, Japan.
Kouseki HiradeCancer Genomic Testing and Treatment Center, Central Japan International Medical Center, Minokamo, Japan.
Seiji SugiyamaDepartment of Pathology, Central Japan International Medical Center, Minokamo, Japan.
Kengo MatsunagaDepartment of Pathology, Central Japan International Medical Center, Minokamo, Japan.
Tetsuya YamadaDepartment of Pathology, Central Japan International Medical Center, Minokamo, Japan.
Yasutaka KatoGenomics Unit, Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan.
Hiroshi NishiharaGenomics Unit, Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan.
Satoshi IshiharaCancer Genomic Testing and Treatment Center, Central Japan International Medical Center, Minokamo, Japan.
Takashi DeguchiDepartment of Urology, Central Japan International Medical Center, Minokamo, Japan.
Saitama International Medical Center · JPHokuto Hospital · JPMitsubishi Electric (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe Von Hippel-Lindau (VHL) gene encodes a protein (pVHL) that plays an important role in proteasome degradation of hypoxia inducible factor α (HIFα) through E3 activation. Accumulation of HIFα by loss of functional pVHL promotes tumorigenesis, thus, VHL has tumor suppressor gene capability in clear cell renal cell carcinoma (ccRCC). VHL is the most frequently mutated gene in ccRCC. The complete loss of VHL is mainly achieved by loss of chromosome 3p, which has a VHL coding region in combination with mutation or hypermethylation of the remaining copy of VHL. Given the risk of constitutional chromosome 3 translocation for RCC, it is important to detect the translocation and understand the mechanism underlying the development of multifocal ccRCC. CASE REPORT: A 67-year-old female patient diagnosed with multifocal RCC underwent robot-assisted partial nephrectomy (RAPN) for three kidney tumors. A cancer gene panel test using next generation sequencing (NGS) detected differential VHL mutations (c.533T>G; p.L178R, c.465_466insTA; p.T157Ifs*3, c.343C>A; p.H115N), while VHL mutation was not detected in peripheral blood DNA. A tendency toward copy number loss of genes on der(3) was also detected in all tumors, but not in the germline one. A karyotype analysis revealed a germline translocation between 3 and 6, t(3;6)(q12;q14).

conclusionChromosome 3 translocation and loss of derivative chromosome containing 3p and subsequent somatic differential VHL mutations in this case strongly support the previously proposed three-step model to explain the development of familial conventional ccRCC.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsAgedChromosomes, Human, Pair 3FemaleHumansMutationTranslocation, GeneticVon Hippel-Lindau Tumor Suppressor ProteinVHL protein, humanVon Hippel-Lindau Tumor Suppressor ProteinCancer gene panel testchromosomal translocation t(3;6)(q12;q14)hereditary renal cell carcinomamultifocal ccRCCVHL

Identifiers

PMID36316043
PMCPMC9620442
OpenAlexW4308180929

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.